Last reviewed · How we verify

Triamcinolone + Bevacizumab — Competitive Intelligence Brief

Triamcinolone + Bevacizumab (Triamcinolone + Bevacizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Corticosteroid + Monoclonal antibody (anti-VEGF). Area: Ophthalmology.

marketed Corticosteroid + Monoclonal antibody (anti-VEGF) Glucocorticoid receptor; VEGF (vascular endothelial growth factor) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Triamcinolone + Bevacizumab (Triamcinolone + Bevacizumab) — Rubens Belfort Jr.. Triamcinolone reduces inflammation via glucocorticoid receptor activation, while bevacizumab inhibits vascular endothelial growth factor (VEGF) to suppress neovascularization and reduce vascular permeability.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Triamcinolone + Bevacizumab TARGET Triamcinolone + Bevacizumab Rubens Belfort Jr. marketed Corticosteroid + Monoclonal antibody (anti-VEGF) Glucocorticoid receptor; VEGF (vascular endothelial growth factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Corticosteroid + Monoclonal antibody (anti-VEGF) class)

  1. Rubens Belfort Jr. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Triamcinolone + Bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/triamcinolone-bevacizumab. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: